Immunotherapy alone for early non-small cell lung cancer in people who cannot have surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed stage IA non-small cell lung cancer (tumor 3 cm or smaller) and have not yet had any treatment for it.
- Your cancer must have a PD-L1 score of 50% or higher (a test that looks for a protein on cancer cells).
- You must be able to carry out usual daily activities (performance status 0, 1, or 2) and be at least 18 years old.
- You must NOT have certain gene changes (like EGFR, ALK, HER2, RET, ROS1, STK11, or KEAP1) that would make the drug less effective.
- You must not have other serious health problems, such as active autoimmune disease, recent heart attack or stroke, or uncontrolled infections (including HIV, hepatitis B/C, or TB).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.